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Abstract
Objectives. Given the limited data regarding the risk of hospitalization in patients with rheumatic
disease and coronavirus disease 2019 (COVID-19) in Ireland, we used the COVID-19 Global
Rheumatology Alliance (GRA) registry data to study outcomes and their predictors. The primary objec-
tive was to explore potential predictors of hospitalization.
Methods. We examined data on patients and their disease-related characteristics entered in the
COVID-19 GRA provider registry from Ireland (from 24 March 2020 to 31 August 2020). Multivariable
logistic regression was used to assess the association of demographic and clinical characteristics with
hospitalization.
Results. Of 105 patients, 47 (45.6%) were hospitalized and 10 (9.5%) died. Multivariable logistic
regression analysis showed that age [odds ratio (OR)¼ 1.06, 95% CI 1.01, 1.10], number of co-
morbidities (OR¼ 1.93, 95% CI 1.11, 3.35) and glucocorticoid use (OR¼ 15.01, 95% CI 1.77, 127.16)
were significantly associated with hospitalization. A diagnosis of inflammatory arthritis was associated
with lower odds of hospitalization (OR¼ 0.09, 95% CI 0.02, 0.32).
Conclusion. Increasing age, co-morbidity burden and glucocorticoid use were associated with hospi-
talization, whereas a diagnosis of inflammatory arthritis was associated with lower odds of
hospitalization.
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Introduction
Infection with the severe acute respiratory syndrome co-
ronavirus 2 (SARS-CoV-2) and the subsequent coronavi-
rus disease 2019 (COVID-19) has caused considerable
morbidity and mortality worldwide. Patients with rheu-
matic diseases are generally at increased risk of
infection owing to both their disease with the associated
co-morbidities and their immunomodulatory or suppres-
sive treatments [1]. Whether this applies to SARS-CoV-2
infection and the magnitude of any such risk remains
unclear.
The COVID-19 Global Rheumatology Alliance (C19-
GRA) aims to address the knowledge gap about COVID-
19 for patients with rheumatic disease [2]. The C19-GRA
has reported data on the first 600 cases in its physician-
reported case registry [3]. In these patients, glucocorti-
coid doses of prednisolone equivalent 10 mg/day were
associated with increased risk of hospitalization,
whereas TNF-a inhibitors were associated with a
decreased risk of hospitalization [3]. Overall, as with the
general population, the greatest risk of negative out-
comes was associated with increasing age and co-
morbidities.
Geographical variations in COVID-19 outcomes have
been reported [4–8]. Our aim was to report the out-
comes and their determinants in patients in Ireland with
rheumatic disease who developed COVID-19.
Methods
COVID-19 Global Rheumatology Alliance
Data regarding individuals with rheumatic disease who
develop COVID-19 are entered into one of two parallel
international data portals hosted in the USA and the UK.
Details of the C19-GRA registries have been published
previously [2, 3, 9].
Data collection
Patients in this study were entered into the C19-GRA
provider registry from 24 March 2020 to 31 August
2020.
Data collected on baseline rheumatic disease status,
including demographic and clinical variables, were as fol-
lows: age, sex, smoking status, rheumatic disease diag-
nosis, disease activity and co-morbidities. Medications
were categorized as previously described (Supplementary
Data S1, available at Rheumatology Advances in Practice
online) [3]. Rheumatic diseases were categorized as in-
flammatory arthritis, gout, vasculitis, CTDs and others
(Supplementary Data S2, available at Rheumatology
Advances in Practice online). Data collected regarding
COVID-19 infection included the method of diagnosis,
place of diagnosis, COVID-19 symptoms and the out-
comes of COVID-19 disease, including hospitalization,
ventilation and death.
Continuous variables were reported as the median
[interquartile range (IQR)]. Categorical variables were
reported as the number and percentage. In univariable
analyses, differences according to hospitalization status
and mortality were compared using v2 tests or Fisher’s
exact tests, as appropriate, for categorical variables and
Mann–Whitney U-tests for continuous variables. The in-
dependent associations between demographic and dis-
ease-specific features with the odds of COVID-19
hospitalization were estimated using univariable followed
by multivariable-adjusted logistic regression and
reported as odds ratios (ORs) and 95% CIs. We con-
structed two multivariable models. The first model in-
cluded all variables with significant effect sizes (P< 0.05)
in the univariable logistic regression analyses, whereas
the second model was the most parsimonious model in-
cluding age, biologic sex and those variables retaining
statistical significance. We did not proceed to logistic
regression analyses with mortality as the outcome owing
to the small number of deaths.
This study was approved by the Irish National
Research Ethics Committee for COVID-19 (20-NREC-
COV-010). The committee waived the need for written
informed patient consent because the data were fully
anonymized.
Results
The characteristics of the 105 included patients are
shown in Table 1. The median age was 59 years, and
61% were female. The most common rheumatic disease
grouping was inflammatory arthritis (61 of 105, 41.9%)
followed by CTD and others (25 of 105, 23.8%) and
gout (21 of 105, 20%). Co-morbidities were present in
almost two-thirds of patients (67 of 105, 63.8%); the two
most common were hypertension (32 of 105, 30.5%)
and cardiovascular disease (26 of 105, 24.8%). Before
COVID-19 diagnosis, glucocorticoids were prescribed to
15 of 105 (14.3%), conventional synthetic DMARD
(csDMARD) monotherapy to 33 of 105 (31.4%) and bio-
logical DMARDs (bDMARDs) or targeted synthetic
Key messages
. Increasing age, co-morbidity burden and glucocorticoid use are associated with higher odds of hospitalization.
. A diagnosis of inflammatory arthritis is associated with lower odds of hospitalization.
. Insights from this study can help direct local strategies for the management of coronavirus disease 2019 in this
patient group.
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TABLE 1 Characteristics of patients with rheumatic disease diagnosed with coronavirus disease 2019, for all participants








n (%) n (%) n (%)
Biologic sex
Female 64 (61.0) 39 (61.9) 24 (38.10) 0.054
Male 41 (39.0) 17 (42.5) 23 (57.5)
Age, years
18–29 3 (2.9) 2 (66.7) 1 (33.3) <0.001†
30–49 25 (23.8) 21 (84.0) 4 (16.0)
50–65 32 (30.5) 22 (71.0) 9 (29.0)
>65 45 (42.9) 11 (25.0) 33 (75.0)
Median (IQR) 59 (27) 51 (18) 75 (21) <0.001‡
Most common rheumatic disease diagnosesa
Inflammatory arthritisb 61 (41.9) 45 (75.0) 15 (25.0) <0.001
Gout 21 (20.0) 0 0 21 (100.0) <0.001
CTD and otherb 25 (23.8) 11 (45.8) 13 (54.2) 0.338
Most common symptomsc
Asymptomatic 4 (4.6) 1 (25.0) 3 (75.0) 0.621†
Fever 67 (63.8) 37 (56.1) 29 (43.0) 0.645
Cough 76 (72.4) 44 (58.7) 31 (41.3) 0.152
Shortness of breath 57 (54.3) 26 (47.3) 29 (52.7) 0.122
Myalgia 35 (33.3) 24 (70.6) 10 (29.4) 0.020
Number of symptoms, median (IQR) 4 (2) 4 (3) 4 (3) 0.0341‡
No co-morbidities 38 (36.2) 32 (84.2) 6 (15.8) <0.001
Most common co-morbidities
Cancer 4 (3.8) 0 (0.0) 4 (100.0) 0.040†
Cerebrovascular disease 7 (6.7) 0 (0.0) 7 (100.0) 0.003†
COPD/asthma 13 (12.4) 3 (23.1) 10 (76.9) 0.015
Cardiovascular disease 26 (24.8) 8 (32.0) 17 (68.0) 0.010
Diabetes 11 (10.5) 0 (0.0) 11 (100.0) <0.001
Hypertension 32 (30.5) 10 (32.3) 21 (67.7) 0.003
Interstitial lung disease 3 (2.9) 0 (0.0) 3 (100.0) 0.092†
Neurological/neuromuscular disease 3 (2.9) 0 (0.0) 3 (100.0) 0.092†
Obesity 6 (5.7) 4 (66.7) 2 (33.3) 0.686†
Renal disease 10 (9.5) 0 (0.0) 10 (100.0) <0.001
Number of co-morbidities, median (IQR) 1 (2) 0 (1) 2 (2) <0.001‡
Smoking status
Never 62 (59.6) 37 (59.7) 25 (40.3) 0.069
Ever 23 (22.1) 7 (31.8) 15 (68.2)
Unknown 19 (18.3)
Medication before COVID-19 diagnosis
Glucocorticoids 15 (14.3) 2 (14.3) 12 (85.7) 0.001
Glucocorticoid equivalent 10 mg 7 (6.7) 0 (0.0) 6 (100.0) 0.008†
csDMARD monotherapy 33 (31.4) 22 (68.8) 10 (31.2) 0.049
b/tsDMARD (monotherapy or in
combination with csDMARD)
37 (35.2) 28 (75.7) 9 (24.3) 0.001
No complications 19 (18.1) 55 (64.7) 30 (35.3) <0.001
Deceased 10 (9.5) 0 (0.0) 10 (100.0) <0.001†
Values are n (column %) for categorical variables, unless otherwise specified. Column numbers and percentages may not
sum to 100 owing to missing values. aPatients could be diagnosed with more than one rheumatic disease. bThe inflamma-
tory arthritis group was composed of RA (37), PsA (13), axial spondyloarthritis (8), JIA (2) and other inflammatory arthritis
(2). The CTD and others group was composed of SLE (5), PMR (4), SS (4), GCA (4) and others (11). cSymptoms with
frequency >30% are reported. *P-value from Pearson’s v2 test. †P-value from Fisher’s exact test. ‡P-value from Mann–
Whitney U-test. bDMARD: biological DMARD; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus
disease 2019; csDMARD: conventional synthetic DMARD; IQR: interquartile range; tsDMARD: targeted synthetic DMARD.
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DMARDs (tsDMARDs) to 37 of 105 (35.2%). Almost half
of reported cases were hospitalized (47 of 105, 45.6%),
and 10 (9.5%) died.
When compared with patients not hospitalized, hospi-
talized patients were older, with a median age of
75 years compared with 51 years (P<0.001; Table 2). A
higher proportion of patients with gout were hospitalized
(100%, P< 0.001), whereas a lower proportion of
patients with inflammatory arthritis were hospitalized
(25%, P< 0.001). Patients with no co-morbidities had a
lower frequency of hospitalization (6 of 47, 15.8%,
P<0.001), and hospitalized patients had a higher me-
dian number of co-morbidities (median 2 vs 0,
P<0.001). Hospitalization was more common in
patients on glucocorticoids (85.7%, P¼ 0.001), with
patients on 10 mg prednisolone equivalent all hospital-
ized (100%, P¼0.008). Hospitalization was less frequent
among those prescribed csDMARD monotherapy
(31.2%, P¼ 0.049) and those prescribed bDMARDs or
tsDMARDs either alone or in combination with
csDMARDs (24.3%, P¼0.001).
In the multivariable logistic regression model, includ-
ing all variables with significant effects estimates in uni-
variable logistic regression analyses, glucocorticoid use
was associated with higher odds of hospitalization
(OR¼ 18.14, 95% CI 1.13, 290.81, P¼0.041; Table 2). A
diagnosis of inflammatory arthritis was associated with
lower odds of hospitalization (OR¼ 0.18, 95% CI 0.02,
0.95, P¼0.044). In the most parsimonious multivariable
logistic regression model, age (OR¼1.06, 95% CI 1.01,
1.10, P¼0.01), number of co-morbidities (OR¼1.93,
95% CI 1.11, 3.35, P¼0.02) and glucocorticoid use
(OR¼ 15.01, 95% CI 1.77, 127.16, P¼0.013) were asso-
ciated with increased odds of hospitalization. A diagno-
sis of inflammatory arthritis was associated with lower
odds of hospitalization (OR¼ 0.09, 95% CI 0.02, 0.32,
P<0.001). csDMARDs and b/tsDMARDs were not asso-
ciated with hospitalization in the multivariable analysis.
In unadjusted analyses, deceased patients were older
(median 80.5 vs 58 years; P¼ 0.001). No patients with
no co-morbidities died of COVID-19 (0%, P¼ 0.013),
and patients who died had a median of 3.5 co-morbid-
ities (median 3.5 vs 0, P<0.001; Supplementary Table
S1, available at Rheumatology Advances in Practice on-
line). Specific co-morbidities associated with mortality
included cardiovascular disease (23.1%, P¼ 0.014), dia-
betes mellitus (36.4%, P¼ 0.01), hypertension (21.9%,
P¼0.008), renal disease (40%, P¼ 0.007) and interstitial
lung disease (66.7%, P¼0.023).
Discussion
This is the largest report of people with rheumatic dis-
ease and COVID-19 from Ireland. We identified factors
associated with higher odds of hospitalization, including
increasing age, number of co-morbidities, a diagnosis of
gout and baseline glucocorticoid use. A diagnosis of
inflammatory arthritis showed a protective association
with hospitalization.
Our findings of the association of increasing age and
glucocorticoid use with hospitalization are consistent
with the findings from C19-GRA [3]. This highlights that
glucocorticoid use should be limited in favour of longer-
term disease-modifying therapies. The C19-GRA
reported bDMARDs as being associated with a reduced
risk of hospitalization, which has some biologic plausibil-
ity owing to the potential for reduction of the hyperin-
flammatory state seen in severe COVID-19 [3, 10, 11].
Several bDMARDs have been proposed as treatment for
severe COVID-19, but results of many controlled trials
have been disappointing [12, 13]. The RECOVERY and
REMAP-CAP trials have demonstrated evidence of mod-
est benefit from the use of the IL-6 receptor antagonists
tocilizumab and sarilumab in COVID-19 [14, 15]. In our
population, the apparent benefit of both csDMARDs and
bDMARDs in the univariable analysis disappeared after
controlling for the underlying diagnostic group. These
agents, and particularly bDMARDs, are more likely to be
used in patients with a diagnosis of inflammatory arthri-
tis, and the reduced risk of hospitalization with these
agents might represent confounding by indication. The
results of ongoing randomized controlled trials of other
bDMARDs in COVID-19 will provide clarity.
Our study has several limitations. Although the low
number of cases of people with rheumatic diseases and
COVID-19 in Ireland entered in the C-19 GRA registry
limits the power of our study, this study explores associ-
ations between patient and disease characteristics and
outcomes in Ireland. Potential overfitting of multivariable
models can occur with small sample sizes and is one
reason we did not proceed to multivariable analysis for
mortality. Once further cases are entered into the GRA
registries, we will be able to conduct more detailed anal-
yses in the future. As a physician-entered registry, the
C19-GRA is limited by selection bias, with more severe
cases likely to be entered, which is likely to explain why
100% of gout cases were hospitalized. Given that there
is no denominator population for these data, no infer-
ences can be drawn about the incidence of COVID-19
in patients with rheumatic diseases. The C19-GRA is re-
stricted to patients who have both rheumatic diseases
and COVID-19; therefore, no comparisons can be made
between this group and the general rheumatic disease
population or with patients without rheumatic disease
who develop COVID-19. Our finding of gout as a risk
factor for hospitalization, although highly significant be-
cause all gout cases were hospitalized, might reflect se-
lection bias and requires future evaluation. Gout is
usually managed in primary care in Ireland, and given
that the C19-GRA is a rheumatologist-entered registry
these cases could be less likely to be entered. Patients
with rheumatic diseases might have behaved differently
with regard to risk behaviour during COVID-19. In
Ireland, a strict national lockdown was in place for a
large part of the study period (including when most










erick user on 22 July 2021
















Female 0.45 (0.20, 1.02) 0.33 (0.05, 2.23) – 0.34 (0.09, 1.36) 0.128
Age, years 1.08 (1.05, 1.11) 1.04 (0.97, 1.10) 0.224 1.06 (1.01, 1.10) 0.010
Most common rheumatic
disease diagnoses
– – – – –
Inflammatory arthritis 0.11 (0.05, 0.28) 0.14 (0.02, 0.95) 0.044 0.09 (0.02, 0.32) <0.001
Gout – – – – –
CTD and other 1.56 (0.62, 3.92) – – – –
Asymptomatic 0.38 (0.04, 3.77) – – – –
Most common symptoms – – – – –
Fever 0.83 (0.37, 1.85) – – – –
Headache 1.16 (0.05, 0.46) 0.25 (0.02, 3.58) 0.310 – –
Sore throat 0.06 (0.01, 0.29) 0.30 (0.03, 2.79) 0.292 – –
Cough 0.53 (0.22, 1.27) – – – –
Shortness of breath 1.86 (0.84, 4.09) – – – –
Arthralgia 0.23 (0.05, 1.13) – – – –
Myalgia 0.36 (0.15, 0.87) 0.92 (0.15, 5.81) 0.931 – –
Chest pain 0.25 (0.07, 0.95) 0.91 (0.08, 9.92) 0.941 – –
Abdominal pain 3.21 (0.59, 17.4) – – – –
Diarrhoea/vomiting/nausea 3.24 (1.28, 8.17) 1.81 (0.26, 12.68) 0.551 – –
Rhinorrhoea 0.18 (0.02, 1.56) – – – –
Irritation/confusion 3.75 (0.38, 37.3) – – – –
Malaise 1.72 (0.71, 4.16) – – – –
Anosmia 0.08 (0.01, 0.64) 0.60 (0.03, 11.49) 0.737 – –
Dysgeusia 0.13 (0.02, 1.08) – – – –
Fatigue 0.49 (0.20, 1.18) – – – –
Number of symptoms, median (IQR) 0.79 (0.66, 0.95) 1.08 (0.59, 1.99) 0.798 – –
No co-morbidities 0.11 (0.04, 0.30) 0.76 (0.09, 6.58) 0.802 – –
Most common co-morbidities – – – – –
Cancer – – – – –
Cerebrovascular disease – – – – –
COPD/asthma 4.77 (1.23, 18.54) 3.09 (0.16, 60.07) 0.456 – –
Cardiovascular disease 3.40 (1.31, 8.85) 0.11 (0.01, 1.88) 0.129 – –
Diabetes – – – – –
Hypertension 3.71 (1.52, 9.08) 0.56 (0.04, 7.94) 0.668 – –
Interstitial lung disease – – – – –
Neurological/neuromuscular disease – – – – –
Obesity 0.58 (0.10, 3.30) – – – –
Psychiatric condition – – – – –
Renal disease – – – – –
Number of co-morbidities, median (IQR) 3.01 (1.92, 4.72) 2.99 (0.59, 15.02) 0.184 1.93 (1.11, 3.35) 0.020
Smoking status – – – – –
Never Reference – 0.889 – –
Ever 3.17 (1.18, 8.89) 1.19 (0.10, 13.68) – – –
Medication before COVID-19 diagnosis – – – – –
Glucocorticoids 9.26 (1.95, 43.89) 18.14 (1.13, 290.81) 0.041 15.01 (1.77, 127.16) 0.013
Glucocorticoid equivalent 10 mg – – – – –
csDMARD monotherapy 0.42 (0.17, 1.00) – – – –
b/tsDMARD (monotherapy or in
combination with csDMARD)
0.24 (0.10, 0.58) 1.36 (0.19, 9.72) 0.557 – –
aMultivariable model, including all variables with significant effect estimates in the univariable logistic regression analyses.
bMost parsimonious multivariable model, including age, biologic sex and only those variables retaining statistical signifi-
cance. bDMARD: biological DMARD; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease 2019;
csDMARD: conventional synthetic DMARD; IQR: interquartile range; OR: odds ratio; tsDMARD: targeted synthetic DMARD.
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cases were reported). Individuals judged to be at high
risk at the start of the pandemic, including many rheu-
matic diseases, were specifically advised to stay at
home as much as possible and to avoid social interac-
tions [16].
In conclusion, our findings confirm that increasing
age, co-morbidity burden and glucocorticoid use are as-
sociated with hospitalization with COVID-19 in patients
with rheumatic diseases. An underlying diagnosis of in-
flammatory arthritis appears to be associated with lower
risk of hospitalization. The previously reported beneficial
effects of bDMARDs might be mediated by underlying
diagnosis rather than a specific effect.
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